All In Biotech

Drug Trial Radar · NCT05064878

A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Examine The Efficacy And Safety Of ZX008 In Subjects With CDKL5 Deficiency Disorder Followed By An Open-Label Extension

Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

87

Actual

Start

Mar 8, 2022

Primary completion

Nov 8, 2027

Study completion Nov 8, 2027

Sponsor

Lead sponsor
Zogenix, Inc.Industry
Sponsor type
Industry
First posted
Oct 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3 Study to examine the efficacy and safety of ZX008 in children and adults with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD).

Conditions

  • CDKL5 Deficiency Disorder
  • Generalized Tonic Clonic Seizure
  • Epileptic Spasm
  • Refractory Seizures

Interventions

  • FenfluramineDrug

    Fenfluramine is supplied as an oral aqueous solution of fenfluramine hydrochloride.

  • PlaceboDrug

    Matching fenfluramine (hydrochloride) placebo is supplied as an oral solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change from Baseline in Countable Motor Seizure Frequency (CMSF) (Part 1)Time frame: Baseline (28 days), Combined Titration and Maintenance (T+M) Periods (14 weeks)
  2. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) (Part 2)Time frame: Up to OLE1 Treatment Period Post-Dose Safety Follow-up Visit 17 (up to 70 weeks)
  3. Percentage of Participants With Abnormal Physical Examination Findings (Part 2)Time frame: Up to End of Treatment (EoT)/Early Termination (ET) Visit 16 of OLE1 Treatment Period (up to 68 weeks)
  4. Percentage of Participants With Abnormal Neurological Examination Findings (Part 2)Time frame: Up to EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
  5. Percentage of Participants with Positive Response to Self-harm Question (Part 2)Time frame: OLE1 Treatment Period Day 1 to OLE1 Treatment Period Post-Dose Safety Follow-up Visit 17 (up to 70 weeks)
  6. Percentage of Participants with Increase in Valvular Regurgitation from Baseline (except absent to trace) (Part 2)Time frame: Baseline (28 days), Cardiac Follow-up Visit 18 (up to 96 weeks)
  7. Percentage of Participants with Pulmonary Arterial Hypertension (PASP > 35 mmHg) at any Time During Treatment on Repeat Testing (Part 2)Time frame: OLE1 Treatment Period Day 1 to EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
  8. Change from Baseline in Laboratory Parameters (Hematology) (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
  9. Change from Baseline in Laboratory Parameters (Hormones) (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
  10. Change from Baseline in Laboratory parameters (Chemistry) (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
  11. Change from Baseline in Laboratory Parameters (Urinalysis) (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
  12. Change from Baseline in Vital Signs (Blood pressure) (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
  13. Change from Baseline in Vital Signs (Heart rate) (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
  14. Change from Baseline in Vital Signs (Temperature) (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
  15. Change from Baseline in Vital Signs (Respiratory rate) (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
  16. Change from Baseline in Body Weight (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
  17. Change from Baseline in Tanner Staging (Part 2)Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
  18. Percentage of Participants with TEAEs (Part 3)Time frame: Up to OLE2 Period Post-Dose Safety Follow-up (up to 200 weeks)
  19. Change from Baseline in Height (Part 3)Time frame: Baseline (28 days), OLE2 Period EoT/ET Visit 23 (up to 198 weeks)
  20. Change from Baseline in Body Weight (Part 3)Time frame: Baseline (28 days), OLE2 Period EoT/ET Visit 23 (up to 198 weeks)
  21. Percentage of Participants with Increase in Valvular Regurgitation from Baseline (except absent to trace) (Part 3)Time frame: Baseline (28 days), Cardiac Follow-up Visit (up to 295 weeks)
  22. Percentage of Participants with Pulmonary Arterial Hypertension (PASP > 35 mmHg) at any Time During Treatment on Repeat Testing (Part 3)Time frame: OLE2 Period Day 1 to EoT/ET Visit 23 of OLE2 Period (up to 198 weeks)

Locations

46 sites in 14 countries. Site status is shown where the registry gives one.

  • Ep0216 154

    Birmingham, Alabama

  • Ep0216 144

    Los Angeles, California

  • Ep0216 101

    San Francisco, California

  • Ep0216 173

    Aurora, Colorado

  • Ep0216 149

    Washington D.C., District of Columbia

  • Ep0216 157

    Atlanta, Georgia

  • Ep0216 113

    Brookline, Massachusetts

  • Ep0216 134

    Detroit, Michigan

  • Ep0216 166

    Chapel Hill, North Carolina

  • Ep0216 164

    Cleveland, Ohio

  • Ep0216 120

    Philadelphia, Pennsylvania

  • Ep0216 124

    Memphis, Tennessee

  • Ep0216 171

    Austin, Texas

  • Ep0216 2505

    Linz, Austria

  • Ep0216 804

    Brussels, Belgium

  • Ep0216 801

    Edegem, Belgium

  • Ep0216 2802

    Tbilisi, Georgia

  • Ep0216 902

    Bielefeld, Germany

  • Ep0216 909

    Kehl-kork, Germany

  • Ep0216 908

    Kiel, Germany

  • Ep0216 901

    Vogtareuth, Germany

  • Ep0216 1803

    Dublin, Ireland

  • Ep0216 1909

    Petah Tikva, Israel

  • Ep0216 1906

    Ramat Gan, Israel

  • Ep0216 1904

    Tel Aviv, Israel

  • Ep0216 1201

    Florence, Italy

  • Ep0216 1204

    Genova, Italy

  • Ep0216 1212

    Modena, Italy

  • Ep0216 1206

    Roma, Italy

  • Ep0216 1208

    Roma, Italy

  • Ep0216 1202

    Verona, Italy

  • Ep0216 1512

    Hiroshima, Japan

  • Ep0216 1505

    Niigata, Japan

  • Ep0216 1518

    Omura-shi, Japan

  • Ep0216 1502

    Shizuoka, Japan

  • Ep0216 1401

    Zwolle, Netherlands

  • Ep0216 2104

    Lisbon, Portugal

  • Ep0216 2105

    Porto, Portugal

  • Ep0216 1103

    Barcelona, Spain

  • Ep0216 1117

    Madrid, Spain

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.